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Recent studies suggest an increasing prevalence of pulmonary nontuberculous mycobacteria
(NTM) disease. In the absence of prevalence and cost data, the public health burden of pulmo-
nary NTM disease is difficult to assess. The goal of this study was to assess costs associated with
NTM disease treatment and to identify risk factors associated with increased costs. Records
from subjects with pulmonary NTM disease enrolled in a natural history protocol were
abstracted for presenting symptoms, comorbidities, microbiology, and treatment histories.
Antibiotic frequency, duration, adverse reaction, and costs were noted, the total antibiotic
burden and cost were calculated, and risk factors associated with high costs were analyzed.
From Jan 2004 to Dec 2005, 33 subjects were enrolled; 27 met disease criteria and had suffi-
cient data to assess antibiotic use. Mycobacterium avium complex was present in 89% and
Mycobacterium abscessus was present in 21% of subjects. Subjects received a median of 5
(1e10) antibiotics. Adverse effects were common seen in up to 50% with common antibiotics
and up to 100% with uncommonly used antibiotics. Median burden of treatment was 2638
(84e7689) drug-days and the median total cost per patient was $19,876 ($398e70,917).
Subjects with high treatment costs had an adjusted 9.5 fold (95% CI 1.5e97.2) likelihood of
having M. abscessus and a 4.2 fold (95% CI 0.6e59.3) increased likelihood of having moregy Unit, Laboratory of Clinical Infectious Diseases, Qrtrs 15B-1, 8 West Dr., MSC 2665, Bethesda,
3058; fax: þ1 301 480 4507.
.gov (D.R. Prevots).
hed by Elsevier Ltd.
Nontuberculous mycobacteria antibiotic treatment cost 1449extensive disease. Pulmonary NTM represent an underappreciated disease burden in the US
population, with an associated treatment cost comparable to that for other chronic diseases
of infectious origin such as HIV/AIDS.
Published by Elsevier Ltd.Introduction
The public health burden of pulmonary nontuberculous
mycobacteria (P-NTM) disease cannot be accurately
assessed in the absence of data on prevalence and treat-
ment cost. These data are essential for allocation of
research funding and creation of public health policy
addressing control of this emerging disease. Population-
based surveys conducted by the CDC during 1981e1983
estimated the prevalence of P-NTM disease at 1e2 cases
per 100,000 persons in the US1; a similar survey from 1993
to 1996 reported an annual case rate of 7e8/100,000.2 A
more recent retrospective analysis from Canada found an
annual increase in NTM isolate prevalence of 8.4% from
1997 through 2003.3 Similar trends have been noted in other
areas of the world.4e9
Guidelines published by the American Thoracic Society
and the Infectious Diseases Society of America (ATS/IDSA) for
the diagnosis, treatment and prevention of P-NTM infections
predict a good outcome for patients who tolerate therapy;
however, they acknowledge the frequent occurrence of
adverse drug reactions that make compliance with a multi-
drug regimen challenging.10 The actual antibiotic prescrip-
tion practices and associated costs have never been system-
atically analyzed. To better estimate costs of antibiotic
treatment associated with NTM disease and identify factors
associated with increased cost, we analyzed data from
a cohort of patients enrolled in a NTM natural history study.
Methods
Study population
Subjects were adult HIV-seronegative patients enrolled in
an IRB-approved natural history study of NTM at the
National Institutes of Health (NIH). Patients had been
recruited through listing in the NIH announcement of
protocols, on clinicaltrials.gov, and by self or physician
referral. To allow at least 18 months of follow-up, we
included patients enrolled between January 1st 2004 and
December 31st 2005. We included only subjects who met
ATS/IDSA diagnostic criteria for P-NTM disease at initial
diagnosis.10
Data collection
Symptom, comorbidity, mycobacteriology, and treatment
histories were abstracted from all available records. A
detailed history of antibiotic usage from the time of diag-
nosis to the date of abstraction in August 2007 was recon-
structed for each patient. Data included the antibiotic
name, dosage, duration, and reasons for discontinuation or
dose modification. Patients with insufficient information toreconstruct a complete treatment history or who were not
treated were excluded.
Severity assessment
Nomeasure has been validated for the assessment of severity
in P-NTM infections. Chest computed tomography (CT) scans
obtained at the time of initial evaluation at the NIH were
independently reviewed and categorized retrospectively by
two investigators (GB, KNO) as normal, mild, moderate or
severe based on the numbers of lobes affected, and the
presence of nodular bronchiectasis or cavities11 (Fig. 1).
Cost data
Wholesale prices of antibiotics as reported by all available
manufacturers were obtained from the ‘‘Red Book 2007:
Pharmacy’s Fundamental Reference’’. For drugs with
multiple manufacturers, we calculated an average cost.
Costs of administration (e.g. nursing care, intravenous
access devices) were not evaluated.
Data analysis
For each antibiotic we calculated the frequency of use,
frequency of adverse reactions requiring discontinuation or
dose reduction, mean duration of treatment, and mean
cost per patient-month of treatment. Duration of treat-
ment was calculated from the date of initial prescription
until the end of treatment, discontinuation, or the date of
data abstraction (if treatment was still ongoing). For each
subject we calculated the total duration of treatment
(including time before and after enrollment at the NIH) and
the number and type of antibiotics used. The total antibi-
otic treatment burden for each subject was then calculated
as the sum of the number of days on each drug (drug-days).
The monthly burden was defined as the total burden
divided by the number of months of follow-up. The total
antibiotic cost was defined as the total number of drug-days
for each drug, multiplied by the cost for the corresponding
drugs, and summed for all prescribed drugs combined. The
monthly cost was defined as the total cost divided by the
number of months of follow-up on treatment. We defined
‘‘high treatment cost’’ as a monthly medication cost above
the 75th quartile for our data set. For analysis of the
association of organism with cost, any patient with Myco-
bacterium abscessus was grouped in the M. abscessus
category, regardless of other organisms found. We calcu-
lated odds ratios (OR) for the association between high
treatment cost and the CT severity score and mycobacterial
species. To assess the statistical significance of the ORs, we
used Fisher’s exact test, with statistical significance
assessed at p< 0.05. Statistical analyses were conducted
using SAS V8.02 (SAS Institute Inc, North Carolina).
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Figure 1 (a) CT findings. NormalZ no nodular bronchiectasis or cavitary disease; these subjects received on average, 5 months
of treatment before enrollment at the NIH. MildZ nodular bronchiectasis limited to less than 3 lobes with no cavitary disease.
ModerateZ nodular bronchiectasis involving 3 or more lobes and/or cavitary disease limited to one lobe. SevereZmultilobar
cavitary disease regardless of presence or extent of nodular bronchiectasis. For the purposes of this categorization, the lingula was
considered a separate lobe. (b) Distribution of organism among persons with moderate/severe disease. (c) Distribution of organism
among persons with mild/moderate disease.
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A total of 33 adult patients with P-NTM disease were
enrolled in the natural history protocol during the period of
interest. Of these, 27 were included in this analysis. Two
patients were excluded due to insufficient documentation
of treatment prior to enrollment, three were lost to follow-
up within 18 months of enrollment, and one patient was
never treated. The median age at enrollment was 59 years
(range 26e82), and 24 (89%) subjects were female. Patients
were followed a median of 53 months (range 19e151) from
initial diagnosis and 28 months (19e40) from enrollment at
NIH to data abstraction (Table 1). Of these 27 patients, 3
died during follow-up. Of the remaining 24, 13 were still
receiving antibiotic treatment.Clinical
Detailed documentation of clinical presentation at the time
of initial diagnosis was not available for all patients. At thetime of enrollment to the NIH natural history protocol, five
patients (19%) reported no symptoms, 16 (59%) had between
one and three symptoms, and six (22%) reported more than
three symptoms, the most common being cough (78%),
hemoptysis (44%), and fatigue (37%) (Table 1). Sixty-seven
percent of subjects had no comorbid conditions. Seven (26%)
had at least one comorbidity and three (11%) had two condi-
tions. Immunosuppressive conditions were themost common:
chronic steroid use (>5 mg of prednisone or equivalent daily)
and/or past medical history of cancer (breast nZ 2, colon
nZ 1) were reported in five patients. Alpha-1 antitrypsin
(A1AT) deficiency or mutations in the Cystic Fibrosis
Transmembrane Conductance Regulator (CFTR) gene were
found in four patients; no patients had diagnosis of cystic
fibrosis. Three patients had COPD or asthma and one subject
had a history of pulmonary tuberculosis treated with a full
course of therapy in the distant past.
Three subjects (11%) had a normal CT scan at the time of
NIH enrollment; these patients had an average of five
months of treatment prior to being seen at NIH. Eight (30%)
subjects were classified as having mild disease and the
Table 1 Patient characteristics.
n (%)
Sex
Female 24 (89)
Median age (range) 59 (26e82)
Clinical findings
Cough 21 (78)
Hemoptysis 12 (44)
Fatigue 10 (37)
Weight loss 9 (33)
Fever 8 (30)
Night sweats 7 (26)
Comorbidities & past medical history
None 18 (67)
Immunosuppression 5 (19)
COPD 2 (7)
Asthma 1 (4)
History of tuberculosis 1 (4)
AAT deficiency 1 (4)
CFTR mutations 1 (4)
Mycobacterium species
Mycobacterium avium complex 24 (89)
Mycobacterium abscessus 6 (22)
Othera 5 (19)
Number of species isolated
Single species 18 (67)
Months of follow-up Median (range)
From initiation of treatment 53 (19e151)
From enrollment at NIH 28 (19e40)
COPD: chronic obstructive pulmonary disease; AAT: alpha-1
antitrypsin; CFTR: cystic fibrosis transmembrane conductance
regulator.
a Refers to the following species isolated only in combination
with multiple isolates of M. avium complex: Mycobacterium
xenopi, Mycobacterium fortuitum, Mycobacterium gordonae,
Mycobacterium scrofulaceum.
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nodular bronchiectasis involving three or more lobes and
was classified as moderate to severe disease (Fig. 1). The
agreement between the two reviewers was 85%, with
a Kappa of 69%. Using the results of the scoring from the
second reviewer would not have changed these findings, as
the total number of patients in the severe/moderate
category would have increased by only one.
Mycobacteriology and clinical/radiographic findings
A single NTM species was isolated from 19 (70%) subjects
(Table 1). Mycobacterium avium complex (MAC) was most
common, comprising 56% of infections as a single pathogen,
and 89% of infections either alone or in combination with
other species. M. abscessus was the second most common,
identified in 21%. Other organisms (Mycobacterium xenopi,
Mycobacterium fortuitum, Mycobacterium gordonae, and
Mycobacterium scrofulaceum) were recovered from sputum
and bronchoalveolar lavage samples only in the background
of multiple prior MAC cultures. Three patients had positive
cultures for both MAC and M. abscessus. Overall 16 (59%)patients had moderate/severe disease (Fig. 1a). Of these 16
with moderate severe disease, 5 (31%) had M. abscessus
(Fig. 1b), Among the 11 persons with mild disease 1 (9%) had
M. abscessus identified (1c).Antibiotic treatment for NTM and associated costs
Overall, 25 different antibiotics were prescribed (Table 2).
Subjects received a median of 5 (range 1e10) antibiotics.
The four most commonly prescribed antibiotics were
ethambutol (85%), rifampin (64%), clarithromycin (64%)
and azithromycin (25%). These relatively inexpensive drugs
are readily available and easily administered. Courses of
treatment with these four most commonly prescribed
drugs were on average (760 days) longer than treatment
with the four drugs (linezolid, ertapenem, cefoxitin, and
imipenem) with an average monthly cost> $1000 (174
days). Five of 6 patients whose treatment cost was over
the 75th quartile received at least one (median 2, range
1e2) of these most expensive drugs. These drugs were
part of the initial antibiotic regimen for only one patient.
Only one patient whose treatment cost was above the 75th
quartile was never treated with costly drugs; his treat-
ment was more expensive because of lengthy duration.
Overall, the proportion of patients with drug interruptions
due to side effects ranged from 17% for ciprofloxacin to
75% for levofloxacin. For the most commonly prescribed
drugs, the frequency of these reported interruptions
ranged from 18% for azithromycin to 50% for ethambutol
(Table 2).
The median burden of treatment for the entire cohort
was 2683 (range 84e7689) drug-days (Fig. 2). After
adjustment for variable follow-up, the monthly treatment
burden was 68 (1e109) drug-days, roughly equivalent to
treatment with two drugs per day over the entire follow-
up period. The median overall medication cost per patient
was $19,876 ($398e70,917) with a median monthly treat-
ment cost of $481 ($3e2075). However, the cost varied
greatly by infecting organism. Patients infected with MAC
had an overall median medication cost of $14,730
compared with an overall median cost of $47,240 for those
infected with M. abscessus. Patients with more severe
disease had an overall cost of $28,738 compared with an
overall median cost of $10,706 for those who had mild
disease.
High monthly treatment cost (>75th quartile, i.e. $759)
was not associated with age, number of comorbidities, or
number of symptoms at the time of enrollment. However,
subjects with high treatment costs were 12 (ORZ 12.0;
95% CI 1.5e97.2) times more likely to have M. abscessus
(Table 3). Subjects with a high treatment cost were six
fold more likely to have extensive disease based on CT
findings, although this association was not statistically
significant (95% CI 0.6e59.3). To assess the effects of each
factor on cost, we constructed a multivariate logistic
regression model including organism and CT disease
severity. We found an adjusted nine fold increased likeli-
hood of M. abscessus infection (adjusted OR 9.5; 95% CI
1.1, 82.4) and a non-significant four fold likelihood of
moderate to severe disease (adjusted OR 4.2; 95% CI 0.4,
49.4) among those with high cost.
Table 2 Antibiotic usage and cost.
Antibiotic N Interruptions due
to side effects (%)a
Average duration
of treatment (drug-days)
Average cost
per patient ($US)
Average monthly cost
($US per month of treatment)
Ethambutol 24 12 (50) 739 2897 119
Rifampin 18 8 (45) 845 2852 103
Clarithromycin 18 6 (33) 660 5792 267
Azithromycin 17 3 (18) 793 6251 240
Moxifloxacin 10 3 (30) 779 8676 339
Amikacinc 10 5 (50) 334 1767 161
Rifabutin 7 5 (71) 124 986 242
Ciprofloxacin 6 1 (17) 369 3463 286
Otherb 5 1 (20) 241 4405 556
Levofloxacin 4 3 (75) 123 1714 424
Clofazimine 4 1 (25) 291 196 21
Imipenemc 3 e 330 35,338 3259
Isoniazid 3 e 148 28 6
Linezolid 3 2 (67) 315 13,445 1299
Cefoxitinc 2 2 (100) 97 10,849 3403
TMP/SMX 2 e 186 56 9
Streptomycinc 2 e 228 542 72
Amox/Clav 2 e 118 938 242
Ertapenemc 1 e 6 359 1821
$US: US dollars; TMP/SMX: trimetropin/sulfamethoxazole; Amox/Clav: amoxicillin/clavulanate.
a Number of patients that had to interrupt or decrease the dose of antibiotic due to side effects attributed to the drug.
b Other: ofloxacin, pyrazinamide, clindamycin, doxycycline, aztreonamc, ceftazidimec.
c Drug administered intravenously or intramuscularly (streptomycin).
Figure 2 Burden of treatment and medication costs. Box and whisker plots where the plus signs and horizontal lines within the
boxes represent the mean and median values, the top and bottom of boxes represent the 75th and 25th percentiles, the vertical
lines represent the 95th and 5th percentiles, and the circles represent outliers. Data are categorized for all subjects, those with
Mycobacterium abscessus (MABS), and those with Mycobacterium avium complex (MAC) and represent: (a) Total burden of
treatment per patient in drug-days (sum of the number of days on each drug); (b) Monthly burden of treatment (total burden
divided by the number of months of follow-up); (c) Total medication costs per patient; (d) Monthly medication costs per patient.
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Table 3 Association of severity and infecting organism with high treatment cost.
Variable High cost/total OR 95% CI Adjusted OR Adjusted 95% CI
Organism
Mycobacterium abscessus 4/6 12.0* 1.5e97.2 9.5* 1.1e82.4
Non-M. abscessus 3/21 1.0
CT Findings
Moderate/severe 6/16 6 0.6e59.3 4.2 0.4e49.4
Normal/mild 1/11 1.0
*p< 0.05.
Nontuberculous mycobacteria antibiotic treatment cost 1453Discussion
Cost is a critical factor in evaluating the public health
burden of any condition. Our study represents the first
systematic description of patterns of antibiotic prescription
and treatment costs associated with P-NTM disease. We
found the number and type of antibiotics prescribed were
consistent with ATS/IDSA recommendations, and the cost of
these antibiotics as assessed during a median follow-up
period of over four years was approximately $20,000 with
an average monthly cost over $500. Infecting organism was
the factor most strongly associated with antibiotic cost; the
rapid growing organisms (e.g. M. abscessus) have quite
different and expensive treatment recommendations. The
data also suggest that severity of disease is predictive of
cost, though the association based on CT severity in this
small sample was not statistically significant.
In a retrospective cohort of patients with P-NTM disease,
Huang et al. emphasized the chronic nature of the diseaseFigure 3 Three examples of NTM treatment courses. Frequent i
cation of discrete antibiotic courses difficult.and found the recommended macrolide-based regimens
have a significantly high rate of adverse reactions which
compromise tolerability and ultimately result in limited
therapeutic success.12 In our study population, ethambutol,
rifampin, clarithromycin and azithromycin were the drugs
most widely prescribed, in concordance with the ATS/IDSA
recommendations for therapy of MAC.10 The frequency of
adverse effects requiring a dose reduction or discontinua-
tion of the drug was as high as 50% for the most commonly
prescribed antibiotics, and up to 100% for less commonly
used drugs (Table 2). The occurrence of adverse effects not
requiring treatment changes was much higher. Gastroin-
testinal symptoms (epigastric discomfort, nausea and
vomiting) were the most common complaints. Toxicity was
higher than previously reported for these drugs used for
other diseases or populations13,14 and may reflect complex
interactions of multiple concomitant drugs or a particular
vulnerability of this population. It may also relate to
severity of disease or lack of response to initial treatmentnterruptions, substitutions, and dosage changes made identifi-
1454 G.J. Ballarino et al.as reasons for referral to the NIH protocol. The guidelines
recommend treatment until 12 consecutive months of
negative sputum cultures are obtained. Frequent inter-
ruptions and substitutions of antibiotic classes occurred at
variable intervals. This made it difficult to identify discrete
courses of treatment throughout the follow-up period.
Examples of treatment regimens which demonstrate the
number of drugs and the length of treatment with each are
displayed in Fig. 3.
Our study likely underestimates the true cost of treating
NTM pulmonary infections. The direct medication cost did
not include the cost of administering intravenous antibi-
otics such as amikacin. We also did not include the cost of
outpatient visits or hospitalizations (productivity time lost,
etc). A recent analysis of the prevalence and economic
burden of bronchiectasis (commonly associated with NTM)
utilizing a health-care claims database, estimated that drug
costs (majority were antibiotics) accounted for only 18% of
the total health-care costs.15 Our study population is likely
to be biased by recruitment to a tertiary research referral
center; if they are more likely to have severe disease, we
may have overestimated cost. Severity was likely not
significantly strongly associated with cost in this study for
several reasons. First, the small sample size reduced the
ability to detect a statistically significant association. Our
measure of severity, CT scans, was assessed at enrollment
to the NIH natural history study when most patients had
already started treatment (median 23 months), and
therefore their lesions may have appeared to be milder.
Prior surgeries were not considered in the severity cate-
gorization; therefore, a patient with localized cavitary
disease from M. abscessus infection who underwent surgical
resection prior to enrollment and had nodular bronchiec-
tasis confined to one or two remaining lobes would have
been classified as having mild disease. Lastly, the oppor-
tunity for therapeutic intervention is never defined solely
on CT changes but considered within a broader clinical
picture; a more comprehensive scoring system that includes
clinical, radiographic and analytical data is likely to be
more accurate in determining true disease severity and
predict cost of disease.
The overall median monthly cost of $481 corresponds to
an annual cost of $5772 ($5196 for those infected with MAC
and $11,796 for those infected with M. abscessus).
Comparisons of these costs to those for treating other
similar diseases are limited by differences in study settings
and methods. A prospective cohort study of the cost-
effectiveness of treating multi-drug-resistant tuberculosis
(MDR-TB) in the Philippines found an average per patient
cost of $1557 assessed in 2002 for patients who had been
followed over a three-year period.16 Pulmonary infections
with NTM are analogous to a chronic disease requiring non-
discrete courses of medical treatment during prolonged
periods of time. Treatment of P-NTM infections may be
more comparable to treatment of HIV/AIDS, a chronic
condition of infectious origin. Data from the HIV Research
Network were used to estimate the annual cost of anti-
retroviral therapy (ART) at $18,396 across their entire
population of patients.17 A similar study estimated annual
average costs of ART at $12,665 per patient based on
National AIDS surveillance data during 2002e2003.18
Detailed follow-up data on persons living with HIV/AIDShave allowed estimation of the lifetime cost of treatment.
If we assume a relatively high survival with lifetime treat-
ment, the overall cost may be similarly increased. With
a median annual cost of $5772 and a median cumulative
cost of nearly $20,000 over a 4-year treatment course,
the cost of treating P-NTM infections may be comparable to
the cost of treating MDR-TB and HIV/AIDS. With a charac-
teristically chronic course and an apparent increasing
prevalence, our findings emphasize the potential impact of
P-NTM disease in public health and underscore the rele-
vance of P-NTM infections to all pulmonary and infectious
disease practitioners.
In summary, P-NTM represent an underappreciated
disease burden in the US population, with an associated
cost comparable to that for other chronic diseases of
infectious origin such as HIV/AIDS. Further data on P-NTM
prevalence in varied populations are needed to better
estimate the true burden of treating NTM in the US.
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